The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL.
Bull SB, et al. Among authors: pinnaduwage d.
J Clin Oncol. 2004 Jan 1;22(1):86-96. doi: 10.1200/JCO.2004.09.128.
J Clin Oncol. 2004.
PMID: 14701769